Edge Therapeutics, Evonik Industries Granted EG-1962 Composition Of Matter Patent
BERKELEY HEIGHTS & PARSIPPANY, N.J.--(BUSINESS WIRE)--Clinical-stage biotechnology company Edge Therapeutics, Inc. and leading specialty chemicals company Evonik Corporation announced today that they have received a U.S. Patent No. 8,821,944 (the ‘944 patent) expiring July 2033 covering EG-1962, Edge’s lead product candidate in development to potentially improve patient outcome after a ruptured brain aneurysm.
The ‘944 patent includes claims that cover compositions containing the Form I polymorph of nimodipine, methods of manufacturing, and methods of use for EG-1962.
“We are pleased that the U.S. Patent and Trademark Office (USPTO) has issued this composition of matter patent, which builds upon our existing intellectual property portfolio for EG-1962,” said Brian Leuthner, Chief Executive Officer and President of Edge Therapeutics, Inc. “Together with our partners at Evonik, we are developing EG-1962 to improve patient outcomes in this vulnerable patient population.”
Help employers find you! Check out all the jobs and post your resume.
The ‘944 patent includes claims that cover compositions containing the Form I polymorph of nimodipine, methods of manufacturing, and methods of use for EG-1962.
“We are pleased that the U.S. Patent and Trademark Office (USPTO) has issued this composition of matter patent, which builds upon our existing intellectual property portfolio for EG-1962,” said Brian Leuthner, Chief Executive Officer and President of Edge Therapeutics, Inc. “Together with our partners at Evonik, we are developing EG-1962 to improve patient outcomes in this vulnerable patient population.”
Help employers find you! Check out all the jobs and post your resume.